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Alzheimer’s disease (AD), the most common chronic and progressive neurodegenerative disorder, is characterized by extracellular
deposits of amyloid 𝛽-peptides (A𝛽) and intracellular deposits of hyperphosphorylated tau (phospho-tau) protein. Ceramides,
the major molecules of sphingolipid metabolism and lipid second messengers, have been associated with AD progression and
pathology via A𝛽 generation. Enhanced levels of ceramides directly increase A𝛽 through stabilization of 𝛽-secretase, the key
enzyme in the amyloidogenic processing of A𝛽 precursor protein (APP). As a positive feedback loop, the generated oligomeric and
fibrillar A𝛽 induces a further increase in ceramide levels by activating sphingomyelinases that catalyze the catabolic breakdown of
sphingomyelin to ceramide. Evidence also supports important role of ceramides in neuronal apoptosis. Ceramides may initiate a
cascade of biochemical alterations, which ultimately leads to neuronal death by diverse mechanisms, including depolarization and
permeabilization of mitochondria, increased production of reactive oxygen species (ROS), cytochrome c release, Bcl-2 depletion,
and caspase-3 activation, mainly by modulating intracellular signalling, particularly along the pathways related to Akt/PKB kinase
and mitogen-activated protein kinases (MAPKs). This review summarizes recent findings related to the role of ceramides in
oxidative stress-driven neuronal apoptosis and interplay with A𝛽 in the cascade of events ending in neuronal degeneration.
1. Introduction to A𝛽, Lipids, and Oxidative
Stress in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurode-
generative disease and the leading cause of dementia in
elderly people. Slow and progressive degeneration of neurons
in brain regions involved in learning and memory results
in gradual cognitive decline, loss of memory, personality
changes, and impairment of normal social and emotional
behaviours [1–3]. In spite of major research efforts, current
therapeutic approaches do not modify the progression of
the disease. Without novel therapeutic improvements, it is
estimated that the number of affected people worldwide will
rise to 100 million by 2050 [4].
Neuropathologically, AD is characterized by the aber-
rant accumulation and deposition of misfolded proteins. In
particular, extracellular neuritic plaques made of aggregated
forms of neurotoxic amyloid 𝛽-peptide (A𝛽) and intracel-
lular deposits of abnormally phosphorylated tau protein are
considered as key hallmarks of AD brain [5–7]. Within
cell membranes, in unique microdomains called lipid rafts,
A𝛽 is derived from the amyloid precursor protein (APP)
through two major steps of enzymatic cleavage [6, 8, 9].
Namely, of particular importance for the pathogenesis of
AD is a shift towards the 𝛽-secretase (BACE1) pathway in
which sequential cleavage of APP first by BACE1 and then
by 𝛾-secretase generates A𝛽 peptide, a 39- to 43-amino acid
fragment. The A𝛽 peptide, especially A𝛽
1–42, is highly prone
to aggregation and self-assembles to form a heterogeneous
mixture of oligomers and protofibrils, ultimately deposited
as fibrils in senile plaques. Small soluble A𝛽 oligomers,
which correlate strongly with disease onset and severity, are
considered as the major neurotoxic species in AD [10–12].
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As APP and both 𝛽- and 𝛾-secretase are integral mem-
brane proteins, it comes to no surprise that membrane lipids
may regulate subcellular trafficking, activity, and metabolism
of these AD related proteins and affect proteolytic processing
of APP and generation of A𝛽 [13]. A deregulation of lipid
metabolismhas been recognized as an increasingly important
factor in the pathogenesis of AD. Numerous studies have
shown that alterations in the composition of the brain’s lipid
profile and cerebral lipid homeostasis are associated with the
disease onset and progression [14–17]. In addition, the single
most important genetic risk factor for late-onset sporadic AD
is the presence of the 𝜀4 allele of the apolipoprotein E (apoE),
the major brain lipoprotein, which mediates transport of
cholesterol and other lipids [18, 19]. Epidemiological and
animal studies suggested that a high-fat diet is a serious risk
factor for the development of the disease, as it may elevate
peripheral cholesterol, perturbate central lipid metabolism,
and increase oxidative stress [20–24]. Among different lipid
classes, ceramides have attracted much attention in recent
years as key contributors in the pathology of AD as they are
able to affect both A𝛽 generation and tau phosphorylation
[25, 26]. Alterations in sphingolipid metabolism that result
in accumulation of long-chain ceramides have been observed
in normal aging and in the brains from AD patients [27].
Furthermore, ceramide- as well as other lipid-lowering drugs
may reduce accumulation of A𝛽 in vitro and in vivo, pro-
viding novel promising avenues for improving therapeutic
effectiveness in AD [28–32].
In addition to increased ceramides, the pathogenesis of
AD is also tightly linked to increased oxidative stress. Oxida-
tive stress is accompanied with mitochondrial dysfunction,
pronounced inflammation, gliosis, axonal degeneration, and
impairment of synaptic transmission that ultimately end
in progressive neuronal loss, predominantly by apoptosis.
Neuronal loss is particularly evident in vulnerable brain
areas such as entorhinal cortex, hippocampal formation,
and association regions of neocortex [33–37]. Evidence sug-
gests that a long quiescent period of progressive oxidative
injury precedes and actually leads to the seemingly sudden
appearance of clinical and pathological symptoms of the
disease [38]. A high-fat diet may play an important role in
accelerating an age-related increase in oxidative stress and
induce changes in energymetabolism and brain function that
promote the development of cognitive alterations including
dementia [23, 39]. Moreover, decreased antioxidant response
may additionally contribute to the high-fat diet-induced
exacerbation of cognitive dysfunction, tightly implicating
oxidative stress as an important mediator in the impairment
of cognitive functions [23].
2. Ceramides in the Pathogenesis of AD
Ceramides are central molecules of sphingolipid biosynthesis
and catabolism. Sphingolipids represent a heterogeneous
class of lipids that contains backbone of sphingoid bases,
a set of aliphatic amino alcohols of which sphingosine is
the most common in mammals [40]. Sphingolipids are
particularly abundant in aforementioned lipid rafts, highly
dynamic membrane microdomains that regulate spatial and
temporal assembly of signalling and trafficking molecules,
acting as platforms for signal transduction [10, 41]. Hence,
beside important role as structural components of eukary-
otic membranes, particularly in the outer leaflet of the
plasma membrane, sphingolipids and their metabolites act
as second messengers in diverse signalling pathways. These
transduction pathways determine differentiation, cell growth,
growth arrest, and apoptosis, depending on the levels and
species of metabolites formed, cell and receptor types, and
downstream targets [17, 30, 42, 43]. Although sphingolipids
represent only a small fraction of the total cellular lipid pool,
even subtle disturbances in their balance may contribute
to the development of neurodegenerative diseases [44–46].
For example, levels of sphingomyelin, the most abundant
sphingolipid in mammalian cells, are increased exclusively
in the cerebrospinal fluid of patients in prodromal AD [47],
while an increased ratio of sphingomyelin to ceramides is
considered as a potential blood-based marker of the disease
progression [48].
Ceramides, as primary metabolic products of sphin-
gomyelin catabolism and the major bioactive molecules of
sphingolipid pathways, also comprise a heterogeneous class
of lipids. They are composed of sphingosine attached to
different fatty acids varying in length from 14 to 26 carbon
atoms. Most commonly, sphingosine is attached to palmitic
(C16) and stearic (C18) non-hydroxy fatty acids [43, 49, 50].
Beside their essential role in signal transduction, they also
act as regulators of synaptic function, contributing to the
maintenance of synapses, dendritic spines, and neuronal
transmission in association with other sphingolipids and
cholesterol in lipid rafts [43, 44, 51].
Ceramide formation occurs via three different pathways:
de novo synthesis, recycling, and degradation (Figure 1).
In the catabolic pathway, ceramides are generated through
the hydrolysis of phosphodiester bonds in sphingomyelin
by sphingomyelinases (SMases). SMases are sphingomyelin-
specific forms of phospholipase C enzymes, located either in
lysosomes or at the plasma membrane. Several isoforms of
SMases have been identified that differ in optimal pH range,
subcellular localization, and cation dependence. In particular,
a Mg2+-dependent neutral SMase, the most prominent form,
is found at the plasma membrane and a Mg2+-independent
neutral SMase is localized in the cytosol, while a ubiquitous
cation-independent acidic SMase is active in the endosomal-
lysosomal compartments [43, 52]. Unusually, the gene for
acidic SMase generates two unique products through the
differential trafficking of a single-protein precursor. One of
these products is commonly studied and already mentioned
lysosomal form, while the other, an alternative acidic SMase,
is secreted extracellularly where it potentially may participate
in the hydrolysis of sphingomyelin in the outer leaflet of
the plasma membrane and bloodstream lipoproteins [42,
53]. Because neutral and acidic SMases can be activated
rapidly and transiently in response to diverse exogenous
and endogenous stimuli, they are considered major pathways
for ceramide generation in early transduction [54]. Both
neutral and acidic SMases are active in neurons, but neutral
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Figure 1: Ceramide formation via de novo synthesis, recycling, and degradation. In the catabolic pathway, ceramides are generated through
sphingomyelin hydrolysis by sphingomyelinases (SMases). In de novo synthesis, serine palmitoyltransferase (SPT) is the rate-limiting enzyme.
In the recycling pathway, sphingosine, the product of sphingolipid catabolism, is salvaged through reacylation, resulting in ceramide
production.
SMases are localized in axons, while acidic SMases are found
predominantly in the neuronal perikarya [30].
Ceramides can also be synthesized by a de novo endoge-
nous biosynthetic pathway that begins with the condensation
of serine and palmitoyl CoA, a reaction catalyzed by the rate-
limiting enzyme serine palmitoyltransferase (SPT), to form
3-ketosphinganine.Thismoiety is further reduced to the sph-
ingoid base sphinganine, which is subsequently N-acylated
to form dihydroceramide, and finally after introduction of
a double bond to the position C4 of the dihydroceramide,
the mammalian type ceramides are formed [42, 43]. At last,
ceramides are generated in an alternative pathway that relies
on the reverse activity of the enzyme ceramidase and is
known as the salvage pathway as catabolic fragments are
reused for biosynthesis. In this recycling pathway, complex
sphingolipids are broken down to ceramide and then by
ceramidase to sphingosine, which is then reconverted by
reacylation to yield ceramide [49, 55].
As previously mentioned, ceramides have been suggested
to be key players in the pathogenesis of AD. Elevated basal
serum levels of particular ceramide species are associated
with a higher risk for developingAD [56]. Increased ceramide
levels are also present in brains of AD patients in comparison
to age-matched neurologically normal control subjects [25,
57, 58]. Importantly, levels of ceramides are found increased
in patients with mild to moderate symptoms, indicating that
alterations in lipid metabolism occur in the early stages
of AD progression [27]. In addition, it appears that serum
ceramides vary according to the time of the onset of memory
impairment [59]. Furthermore, aging itself is accompanied by
a gradual increase in brain A𝛽 content that can be reduced by
inhibitors of neutral SMase [30, 60]. Gene expression abnor-
malities of enzymes involved in sphingolipid metabolism are
observed at different stages of AD progression. In particu-
lar, expression of genes related to ceramide homeostasis is
altered in a way that enzymes participating in the de novo
synthesis of ceramide and in sphingomyelin hydrolysis are
increased as a function of the disease progression [58, 61].
Alterations in sphingolipid metabolism during normal brain
aging and in the brain of AD patients that result in accumu-
lation of long-chain ceramides may contribute to neurotoxic
action of A𝛽 and exacerbate progression of the disease (see
below).
At higher concentrations ceramides promote cellular dys-
function and act as regulatory mediators of programmed cell
death [62]. Short-chain cell-permeable ceramide analogues
(C2-ceramide and C6-ceramide) have been extensively used
in studies aimed at elucidating ceramide-mediated signalling
death pathways and their role in neurodegeneration [63–66].
A specific sphingomyelin synthase SMS1-related enzyme has
been discovered that functions as a regulator of ceramide
homeostasis, probably operating as a ceramide sensor aimed
at protecting cells against ceramide-induced cell death [42,
67]. As phosphorylated derivatives of ceramides, such as
sphingosine-1-phosphate, generally stimulate proliferation
and exhibit antiapoptotic properties, at least in part by
regulating different family members of mitogen-activated
protein kinases (MAPKs), very small shifts in ceramide
metabolism may determine neuronal fate in response to a
variety of stimuli [66, 68, 69].
There are numerous downstream targets of ceramides.
Evidence suggests that ceramides act either by changing
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the organization of cellular membranes or by direct bind-
ing and activation of target proteins. Thus, directly or
indirectly, ceramides regulate MAPKs, protein kinase C𝜁
(PKC𝜁), ceramide-activated protein kinases (CAPK), cer-
amide-activated protein phosphatases (CAPP), cathepsin D,
and diverse phospholipases [43, 70].
3. Ceramides and Oxidative Damage in AD
Several lines of evidence pointed out that generation of
free radicals is one of the major contributors to the neu-
rotoxic effects of ceramides and A𝛽 in AD [27, 71, 72].
Increase in ceramide levels stimulates generation of ROS
in a concentration-dependent manner, establishing a link
between oxidative stress and sphingolipid metabolism with
detrimental consequences for neuronal survival [70]. In neu-
ronally differentiated PC12 cells, it is shown that mitochon-
drial ROS production is an early step in the activation of the
apoptotic sphingomyelin-dependent transduction pathway,
followed by translocation of the transcription factor NF-𝜅B.
Complex 1 of the mitochondrial electron transport chain has
been identified as the origin of free radicals. Antioxidant
treatment abolished ROS production almost completely and
prevented both the NF-𝜅B translocation and neuronal death
[73, 74]. Another study on PC12 cells demonstrated almost
simultaneous increases in ROS, [Ca2+]cyt and [Ca
2+]mit
in ceramide-mediated cell death but found that only the
latter was directly implicated in reduced survival [75]. In
hippocampal primary cultures containing predominantly
astrocytes, ROS levels were also increased in ceramide-
treated cells in a dose-dependent manner, as indicated by
the amount of measured hydrogen peroxide and upregulated
Ddit3 expression, an indicator of cellular oxidative stress [76].
As mentioned before, oxidative stress-induced neuronal
damage is one of the most prominent characteristics of AD
[36, 77–79]. Oxidative stress occurs when cellular antiox-
idant defences are insufficient to keep the levels of ROS
below a toxic threshold. It has deleterious effects on cellular
macromolecules, including proteins, lipids, carbohydrates,
and nucleic acids, causing their structural and functional
alterations, and frequently leading to cell death [78–82].
The brain is particularly vulnerable to oxidative damage due
to its high rate of oxygen consumption, high production
of ROS, limited oxidative defences, low repair mechanisms
activity, and large amount of polyunsaturated fatty acids
(PUFAs) [81, 83]. PUFAs are highly prone to ROS-induced
lipid peroxidation, a chain reaction of free radical formation
in the lipid parts of cellularmembranes. Lipid peroxy radicals
may change fluidity and permeability of cellular membranes
or may directly attack and damage intracellular biomacro-
molecules. 4-Hydroxynonenal (HNE) and malondialdehyde
and acrolein are highly toxic typical end-products of lipid
peroxidation. HNE is considered to be the most toxic alde-
hyde. As a strong electrophile, it readily reacts with thiol and
amino groups of cysteine, histidine, and lysine, leading to
protein damage [84–86].
The role of lipid peroxidation has been repeatedly empha-
sized as one of the major causes of oxidative damage in
AD [35, 87]. When cultured neurons were pretreated with
𝛼-tocopherol (a strong antioxidant) before exposure to A𝛽,
amounts of HNE adducts and long-chain C:18 and C:24
ceramides were significantly lower than in A𝛽-treated neu-
rons, while their survival was enhanced [27]. Accumulation
of HNE is associated with brain aging, and levels of HNE
increase in parallel with AD severity [27, 88, 89]. More-
over, membrane-associated oxidative stress occurs together
with alterations in the composition of brain lipids. In the
postmortem brain increase in HNE is accompanied with
depletion in PUFAs [90]. Epidemiological studies suggest
that increased intake of 𝜔-3 PUFA, such as docosahexaenoic
acid (DHA), reduces the risk of AD and decreases A𝛽 plasma
levels [91, 92]. Animal studies also indicated that dietaryDHA
could protect against A𝛽 production, accumulation, and
downstream toxicity and improve cognitive performance.
Interestingly, the largest reduction in overall plaque burden
was detected in the hippocampus and parietal cortex, the
most affected regions in AD [93, 94]. In contrast, levels
of HNE protein adducts, HNE-lysine and HNE-histidine,
were significantly elevated in the hippocampus of rats with
diet-induced hyperlipidemia [24]. In addition to adduct
formation, toxic effects ofHNE are also related to impairment
of glucose transport and subsequent ATP depletion [95].
Namely, abnormal metabolic changes, including pronounced
decrease in glucose uptake and metabolism, are also charac-
teristic for AD brain (for review see [96–99]). The presence
of othermarkers of oxidative injury, such as protein nitration,
reactive carbonyls, andDNAoxidation, togetherwithmarked
decline in oxidation-sensitive enzymes, was also confirmed
in the brain and cerebrospinal fluid of AD patients by
immunohistochemical and histopathological studies [38, 77,
90]. Moreover, a general reduction in thioredoxin levels
has been observed in AD brains [100], further supporting
the role of oxidative mechanism in the pathogenesis of
AD.
Related to oxidative stress, it is of particular relevance
that elevated levels of copper are present both in brain and
plasma of AD patients [101–103]. In the presence of biological
reductants, Cu2+ can be reduced toCu+, catalyzing the forma-
tion of highly toxic and extremely reactive hydroxyl radicals
via Fenton chemistry [104, 105]. Besides generating ROS,
excess copper may induce alterations in APP processing,
increase production of A𝛽, and impair learning and memory
in animal models [106, 107].
Interestingly, enhanced levels of Cu2+ trigger apoptosis
via activation of acidic SMase and release of ceramides in
hepatocytes [108]. Although it has yet to be confirmed, this
finding might indicate similar association between copper-
induced oxidative stress, SMase activation, and ceramide
increase in neuronal cells. Lipid soluble ceramides generated
by excess hepatic production readily cross the blood-brain
barrier. Lyn-Cook et al. provided supportive evidence that
hepatic ceramide and proinflammatory cytokine produc-
tion play important roles in the pathogenesis of cognitive
impairment and AD-type neurodegeneration by inducing
oxidative stress in the brain, as evidenced by increased HNE
[109].
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Figure 2: Role of ceramides in neuronal apoptosis. Overexpressed ceramides may provoke apoptosis by directly participating in ROS
generation, through modulation of mitogen-activated protein kinases (MAPKs) signalling pathways, and by inhibition of prosurvival
phosphatidylinositol 3-kinase (PI3-K)/Akt pathway via protein phosphatase 2A (PP2A) dephosphorylation, leading to activation of Bad
and glycogen synthase 3𝛽 (GSK-3𝛽). These cascades of biochemical alterations ultimately lead to neuronal death by diverse mechanisms,
including depolarization and permeabilization of mitochondria (Δ𝜓
𝑚
), Bcl-2 depletion and Bax increase, cytochrome c release, and caspase-
3 activation.
Oxidative stress also mediates A𝛽-toxicity that might
be reversed by preincubation with antioxidant N-acetyl-L-
cysteine, a glutathione precursor [110]. Besides, A𝛽 indi-
rectly increases ceramides through oxidative stress-mediated
mechanisms [27]. A recent study by Giraldo et al. suggested
that, in addition to causing damage because of the action of
free radicals, oxidative stress deranges signalling pathways,
in particular p38 MAPK pathway, ending in A𝛽-induced tau
hyperphosphorylation [111].
3.1. Role of Ceramides in Neuronal Apoptosis. Incidence of
apoptosis is elevated in analysis of postmortem AD brains
[112–114]. Overexpressed ceramides may directly participate
in the generation of free radicals in mitochondria and
provokemitochondrial dysfunction and apoptosis (Figure 2).
A recent study has confirmed that ceramide-induced mito-
chondrial failure may lead to oxidative stress and poly(ADP-
ribose) polymerase-1 (PARP-1) activation, a characteristic
biochemical hallmark of apoptosis [115]. Ceramides might
initiate a cascade of detrimental alterations that ultimately
lead to apoptotic cell death by diverse mechanisms, includ-
ing depolarization and permeabilization of mitochondria,
increased production of ROS, cytochrome c release, Bcl-
2 depletion, caspase-3 activation, and inactivation of Akt
followed by dephosphorylation of Bad [116–118].
In particular, the cell-permeable C2-ceramide and C6-
ceramide induce cytochrome c release in isolated mitochon-
dria [119] and primary cortical neurons [117]. Ceramides
do not trigger direct cytochrome c secretion or release but
enhance permeability of the mitochondrial outer membrane
via ceramide channel formation that allows release of all
intermembrane space proteins with a molecular weight up to
60 kDa, including cytochrome c [120, 121]. Beside cytochrome
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c, ceramides induce translocation of other proapoptotic
mitochondrial proteins such as Omi, secondmitochondrion-
derived activator of caspase (Smac), and apoptosis-inducing
factor (AIF) [122]. Formation of these ceramide channels
is sensitive to the free ceramide concentration suggesting
that alterations in ceramide metabolism induce changes
in channels assembling and disassembling, regulating the
permeability of the outer mitochondrial membrane. Open-
ing of the permeabilization transition pore complex, that
results in mitochondrial swelling, rupture of mitochondrial
membranes, and release of cytochrome c, may represent
an additional mechanism mediating apoptotic cytochrome c
release from the intermembrane space of mitochondria into
the cytosol [123, 124]. A decrease in mitochondrial mem-
brane potential is a marker of the opening of the transition
pore complex and has been observed in ceramide-induced
apoptosis of primary cortical neurons [117, 125]. Similarly, in
cerebellar granular cells, C2-ceramide affectedmitochondrial
integrity and induced a decrease inmitochondrial membrane
potential as well as a massive release of cytochrome c [126].
Following release, cytochrome c binds to the apop-
totic protease activating factor-1 (APAF-1) and activates the
caspase cascade [127]. Thus, neuronal death induced by
ceramides is often associatedwith themitochondrial pathway
regulated by caspase-9/caspase-3, as observed in cortical
neuronal cultures and SH-SY5Y human neuroblastoma cells
[116, 117, 125, 126]. In neuroblastoma SK-N-MC cells, N-
acetyl-sphingosine (C2-ceramide) also induced caspase-3-
dependent apoptosis as evidenced by DNA fragmentation
and chromatin condensation [128]. Furthermore, ceramide-
induced increase in mitochondrial calcium was responsible
for activation of caspase-8, cytochrome c release, and death
of nerve growth factor- (NGF-) differentiated PC12 cells [75].
Experiments on SH-SY5Y cells indicate that inhibition of
caspases is not sufficient to block ceramide-induced cell death
completely due to the translocation of AIF from mitochon-
dria to the nucleus, activation of PARP-1, and accumulation
of poly (ADP-ribose), thus supporting the involvement of
caspase-independent programmed cell death in ceramide-
induced injury [70, 129].
Ceramides may act through a variety of signalling path-
ways to modulate cell death. In cortical and HMN1 motor
neuron cells, exposure to ceramides induces serine-threonine
kinase Akt dephosphorylation and deactivation followed by
dephosphorylation and activation of proapoptotic regulators
such as Bad. Furthermore, exposure to ceramides induces
dephosphorylation and activation of glycogen synthase
kinase 3𝛽 (GSK-3𝛽), one of the key enzymes participating
in the phosphorylation of tau protein and also involved in
control of apoptosis [117, 130–132]. Reduction of intrinsic Akt
activity is associated with mitochondrial depolarization and
permeabilization, cytochrome c release, and caspase-3 acti-
vation [117]. A recent study on SH-SY5Y cells also indicated
that ceramide inhibits PI3-K/Akt pathway leading to lower
phosphorylation and activation of GSK-3𝛽 and Bad as down-
stream targets, decreases antiapoptotic Bcl-2, and increases
proapoptotic Bax mRNA/protein levels [70]. C2-ceramide-
induced increase in Bax levels leads to formation of Bax
homodimers, mitochondrial permeabilization, and finally
neuronal death [125, 126]. A potent endogenous antioxidant
S-nitrosoglutathione, aNOcarrier able to terminate oxidative
stress in the brain via a number of different mechanisms,
can neutralize A𝛽- and ceramide-induced toxicity in primary
cortical cultures through multiple prosurvival signalling
cascades, including the activation of cGMP/PKG and PI3-
K/Akt pathways. Activation of these signalling pathways ends
in the induction of antiapoptotic and antioxidative proteins
such as Bcl-2 and thioredoxin [118]. Negative regulation
of kinase Akt through dephosphorylation and concomitant
inhibition of antiapoptotic and prosurvival Akt signalling is
also observed in differentiated PC12 cells after treatment with
C2-ceramide and determined to be the result of enhanced
Akt dephosphorylation by ceramide-activated protein phos-
phatases (CAPP) [133]. In particular, the serine-threonine
protein phosphatases 1 (PP1) and 2A (PP2A) act as CAPP and
exert important role in ceramide-mediated neuronal death
[134–136]. Additional mechanisms responsible for ceramide-
induced neuronal death may involve dephosphorylation
and inactivation of Bcl-2 after activation of mitochondrial
PP2A [137]. Namely, Bcl-2 as a downstream target in Akt
signalling loses its antiapoptotic properties after ceramide-
induced dephosphorylation. Moreover, PP2A indirectly pro-
vokes activation of GSK-3𝛽 via the PI3-K/Akt pathway, and
GSK-3𝛽 in turn might regulate caspase-2 and caspase-8 in
ceramide-induced apoptosis [131]. Overexpression of active
PKB/Akt or Bcl-2 successfully prevented neuronal death in
ceramide-induced caspase-independent apoptosis related to
AIF translocation and PARP activation [129]. However, it
should be mentioned that, despite general beneficial role
of Akt in neuronal survival, increased Akt activation and
hyperphosphorylation of critical Akt substrates have been
observed in AD brain, together with a significant loss and
altered distribution of phosphatase and tensin homologue
deleted in chromosome 10 (PTEN), the major negative
regulator of Akt. Such findings support the involvement of
aberrant control of Akt and PTEN signalling in AD and
suggest that treatments aimed at activating the particular
pathway in AD need to be considered carefully [138, 139].
In addition to Akt kinase, downstream ceramide targets
are c-Jun N-terminal kinases (JNK) that mediate cell death
in AD [140]. Increased ceramide levels have been associ-
ated with JNK activation via phosphorylation in differen-
tiated PC12 cells [141]. The JNK-inhibitor L-JNK1 inhibited
the stimulatory effects of C2-ceramide on caspase-9 and
caspase-3 and prevented C2-ceramide-evoked cell death in
cerebellar granule cells [126]. Transcription factor c-Jun is
the probable target of JNK signalling in ceramide-evoked
death as increased c-Jun phosphorylation was observed in
neuronal nuclei following exposure to ceramide. Moreover,
it seems that p38 and JNK/c-Jun pathways cooperate to
induce neuronal apoptosis [142]. It is demonstrated that
ceramides decrease phosphorylation of extracellular signal-
regulated kinases (ERKs) and their upstream activators
MAPKs kinases (MEKs) and trigger JNK and p38 MAPK
cascades inducing neuronal death through caspase-3 activa-
tion and upregulation of c-jun, c-fos, and p53 [122, 143]. In
another study on SH-SY5Y cells, inhibitors of ERK1/2 and
JNK signalling, UO126 and SP600125, respectively, prevented
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cell death evoked by C2-ceramide confirming the role of
these signalling pathways in neuronal death [70]. Similarly,
in primary cortical neurons p38 and ERK1/2 inhibitors
blocked ceramide-activated apoptotic signalling upstream of
mitochondria, by attenuating release of prodeath effectors
and reducing caspase-3 activation [122].
3.2. Role of A𝛽 in Neuronal Apoptosis. Similar to ceramides,
A𝛽 induces neuronal apoptosis in the brain, in transgenic
mice, and in neuronal cell cultures [25, 144–149]. In par-
ticular, A𝛽 depletes Ca2+ in endoplasmic reticulum that
results in cytosolic Ca2+ overload, decrease in mitochondrial
membrane potential, Bax translocation to mitochondria,
oxidative damage of mitochondrial DNA [150], and acti-
vation of mitochondrial (intrinsic) apoptotic pathway [151].
Evidence also exists for the activation of extrinsic apoptotic
pathway in A𝛽-evoked death. In cortical neurons exposed
to A𝛽, activated JNK is required for the phosphorylation
and activation of the transcription factor c-Jun that in turn
stimulates transcription of several target genes, including
the Fas ligand. Following binding of Fas ligand to its Fas
receptor, a cascade of events leads to caspase activation and
ultimately apoptotic death [147]. Neuronal death provoked
by A𝛽 is preceded by selective alterations in the expression
of the Bcl-2 family of apoptosis-related genes. In one study
A𝛽 significantly reduced expression of antiapoptotic Bcl-w
and Bcl-xL. Accordingly, neuronal death was significantly
increased by Bcl-w suppression but significantly reduced by
Bcl-w overexpression. Downstream of Bcl-w, A𝛽-provoked
apoptosis was characterized by mitochondrial release of
Smac, while JNK turned out to be the upstream mediator of
A𝛽-induced Bcl-w downregulation and Smac release [152].
A𝛽-induced downregulation of Bcl-2 has also been observed,
together with increased Bad phosphorylation [149]. In oligo-
dendrocytes, A𝛽-induced apoptosis following cytochrome c
release involves activation of neutral SMase and increased
ceramide accumulation, upregulation of death protein 5
(DP5/Hrk), a BH3-only proapoptotic protein from Bcl-2
family of apoptotic regulators, and also JNK activation [153].
Upregulation of Hrk gene following ceramide exposure was
also confirmed in neuroblastoma SH-SY5Y cells [70]. In
addition, it is demonstrated that substances acting along the
PI3-K/Akt pathway provide strong neuroprotection against
A𝛽-induced toxicity [154–157]. Interestingly, analyses in APP
transgenic mice revealed a significant decrease in hippocam-
pal Akt phosphorylation at 13 months, at a time that corre-
sponds with plaque appearance and memory impairments in
these mice [158].
3.3. Interplay betweenCeramides, A𝛽 andOxidative Stress. As
alreadymentioned, sphingomyelinases have a prominent role
in sphingolipid metabolism and ceramide formation [159,
160]. Numerous studies have indicated a link between SMase
activation and oxidative stress. It was shown that H
2
O
2
-
induced alterations in redox homeostasis and activation of
neutral sphingomyelinase (N-SMase) result in accumulation
of proapoptotic ceramides in neuronal PC12 cells [161]. In
human primary neurons it was also demonstrated that toxic
oxygen species such as superoxide and hydrogen peroxide
can induce N-SMase activity indicating that ceramide pro-
duction is redox-sensitive [162]. Recently, study of Dotson
II et al. confirmed that neutral SMase-2, the major SMase
activated in inflammation and during oxidative stress, is
indeed the redox-sensitive enzyme and resolved that its basal
activity is influenced by antioxidant enzyme thioredoxin
[163]. Furthermore, expression of both acidic and neutral
SMase was found upregulated in patients with AD in com-
parison with age-matched controls [25, 58, 164]. Even in
normal aging, a membrane-associated N-SMase activity is
upregulated in a brain region-specific pattern, particularly
in hippocampus and striatum [165]. Altered sphingomyelin
metabolism due to increased activity of acidic and neutral
SMases, in combination with induced oxidative stress, ulti-
mately provokes synaptic dysfunction, induces apoptosis, and
contributes to disease pathogenesis [25, 63].
In vitro and in vivo studies have revealed interactive
network of processes establishing the link between levels of
ceramides and A𝛽 generation and aggregation (Figure 3). In
particular, biogenesis of A𝛽 is regulated by the endogenous
pool of ceramides. In fact, evidence exists that membrane-
associated oxidative stress and ceramide production are
required for A𝛽-induced neuronal death [27]. Namely, pre-
treatment of neurons with ISP-1 (an inhibitor of serine
palmitoyltransferase) results in a significant decrease in the
number of neurons killed by A𝛽
1–42, suggesting a pivotal
role of ceramide production in A𝛽-induced neurotoxicity.
Exogenous addition of ceramide mimetics and increased lev-
els of endogenous ceramide induced by N-SMase treatment
directly increased level of A𝛽 by affecting 𝛽-, but not 𝛾-,
cleavage of APP [64]. Synthetic ceramide analogues also may
affect processing of APP to generate A𝛽 [166]. Processing
of APP to A𝛽 peptide occurs predominantly in lipid rafts
and BACE1 is considered as the rate-limiting enzyme in
this process [167]. Membrane ceramides embedded in lipid
rafts facilitate production of A𝛽 by increasing the half-life of
𝛽-secretase (BACE1) through posttranslational stabilization
[64]. Additionally, membrane lipids could directly interact
with the components of 𝛾-secretase complex or APP via their
hydrophobic moieties or polar head groups and underlie the
effects on sphingolipids on secretase activity [13]. Recently, it
was shown that synthetic ceramide analogues may function
as 𝛾-secretase modulators that increase A𝛽
42
production,
emphasizing important effect of the lipid environment on 𝛾-
secretase activity [168]. Ceramide also mediates A𝛽-induced
death in oligodendrocytes. A𝛽-provoked activation of N-
SMase and generation of ceramide can be inhibited by
antioxidantN-acetylcysteine, a glutathione (GSH) precursor,
indicating that activation of N-SMase-ceramide pathway in
glial cells involves oxidative stress after depletion of cellular
GSH stores [169].
In addition, ceramides may affect A𝛽 production by an
alternativemechanism. During aging the brain switches from
using high-affinity tropomyosin-related kinase A (TrkA) to
low-affinity p75 neurotrophin receptor (p75NTR) as themain
receptor for nerve growth factor (NGF). Both receptors
regulate processing of APP. While TrkA decreases 𝛽-cleavage
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Figure 3: Interplay between ceramides, A𝛽 and oxidative stress. Increased levels of ceramides directly increase levels of A𝛽 by increasing the
half-life of BACE1 through posttranslational stabilization. As a positive feedback loop, the generatedA𝛽 induces a further increase in ceramide
levels by activating SMases activities in a ROS-dependent fashion. A𝛽 promotes accumulation of free radicals via NADPH oxidase activation
and glutathione (GSH) depletion and induces membrane oxidative stress leading to generation of 4-hydroxynonenal (HNE), the neurotoxic
product that exacerbates neuronal death through protein adduct formation, impairment of glucose metabolism, and ATP depletion.
of APP, p75NTR enhances APP processing. Ceramide accu-
mulation increases the interaction between p75NTR, NGF,
and ceramides and activates 𝛽-secretase pathway in APP
processing and A𝛽 generation [60].
Soluble and fibrillar forms of A𝛽 generated by ceramide
increase can activate both neutral and acidic SMases pointing
out that ceramide production induces a vicious cycle in
which initial ceramide formation leads to more ceramide
accumulation via A𝛽 [170, 171]. Experiments performed on
human primary neurons and oligodendrocytes support a
more prominent role of N-SMase in A𝛽-induced toxicity
[162, 169]. Similarly, injection of fibrillar A𝛽 is capable of
inducing SMase activity and raising ceramide levels in mouse
hippocampus and neocortex 7 days after administration
[172]. A𝛽-induced production of ceramides is redox-sensitive
as ROS are involved in the activation of N-SMase. A𝛽 induces
NADPHoxidase-mediated production of superoxide radicals
that are further converted to hydrogen peroxide and involved
in the activation of N-SMase [162]. Moreover, A𝛽-mediated
activation of SMases and accumulation of ceramide can be
inhibited by antioxidant molecules such as GSH precursors
and 𝛼-tocopherol and increased by GSH depleters, implying
that A𝛽 activates SMase-ceramide cascade via an oxidative
mechanism [27, 162, 169, 171]. Furthermore, A𝛽may decrease
levels of GSH, the major antioxidant defence system against
toxic oxygen species, thus promoting accumulation of ROS
[146, 151, 173]. In turn, GSH depletion activates N-Smase
activity [159, 174]. Besides, experiments in rat cortical cultures
demonstrated that bacterial SMase decreases the expression
of thioredoxin-1, another redox protein with potent antiox-
idative properties, whose decreased expression might have
detrimental consequences on neuronal survival [65, 149].
As emphasized before, the ability of A𝛽 to raise ceramide
content is particularly associated with increased levels of
membrane oxidative stress. A𝛽 is inserted as oligomers into
the bilayer and serves as a source of ROS, thus inducing
oxidative injury primarily as a result of increased lipid peroxi-
dation [36, 77, 175].Themagnitude of brain lipid peroxidation
is closely related to the extent of neurodegeneration in AD
[27, 88, 89, 176]. Evidence suggests that HNE acts as pre-
dominant mediator of toxic effects of A𝛽 [177]. Remarkable
increases in level of lipid peroxide products, together with
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Figure 4: Interplay between neurons and astroglia in sphingolipid metabolism. Conditioned medium from palmitic acid- (PA-) treated
astrocytes upregulates neuronal 𝛽-secretase (BACE1) leading to A𝛽 accumulation. PA increases de novo synthesis of ceramide and
downregulates glucose uptake in astroglia. PA-induced activation of serine palmitoyltransferase (SPT) leads to production of proinflammatory
cytokines, which after release in surroundingmedia activate neuronal sphingomyelinases (SMases), increase the ceramide pool, and ultimately
lead to increase in A𝛽 accumulation.
enhanced SMase activity and ceramide content, have been
observed in time- and region-specific manner in rat brain
after single injection of A𝛽 [172]. Cutler et al. suggested
that lipid peroxidation is sufficient to induce alterations
in ceramide levels in neurons exposed to A𝛽, as similar
increase in levels of ceramides occurs in neurons exposed to
iron that also catalyzes production of hydroxyl radicals and
membrane lipid peroxidation [27]. Interestingly, formation
of HNE adducts occurs more frequently in the brains of
AD patients who carry the apoE 𝜀4 allele [178]. Moreover,
inhibition of serine palmitoyltransferase, the rate-limiting
step in sphingolipid synthesis, prevents HNE increase and
attenuates A𝛽-induced neuronal death [27].
3.4. Interplay between Neurons and Astroglia in Sphin-
golipid Metabolism. Recent studies have revealed elabo-
rated communication between neurons and glia related to
sphingolipid metabolism (Figure 4). Thus, deregulation of
ceramide metabolism in astrocytes may induce A𝛽 secretion,
as well as tau phosphorylation, in neurons. Namely, in pri-
mary rat cortical neurons treated directly with pathological
concentrations of saturated free acid, palmitic acid (PA), there
was no change in BACE1 level. On the contrary, conditioned
medium from PA-treated astrocytes effectively upregulated
neuronal BACE1, with consequent increase in APP process-
ing and accumulation of the C-terminal fragment of APP.
As cotreatment with antioxidant 1,3-dimethylurea attenuated
PA-induced upregulation of BACE1, it is concluded that
PA increases amyloidogenesis through astroglia-mediated
oxidative stress [179].
Further studies revealed that PA increases de novo synthe-
sis of ceramide in astroglia, which in turn induces production
of A𝛽 in neurons. Inhibition of astroglial-ceramide synthesis
by L-cycloserine, an inhibitor of serine palmitoyltransferase
(SPT), prevented the PA-astroglia-induced BACE1 upregula-
tion and secretion of A𝛽 [180]. The same results are obtained
in TgCRND8 mice, an early-onset AD model encoding the
double mutant form of the APP695. After subcutaneous
administration of L-cycloserine, cortical A𝛽
42
and hyper-
phosphorylated tau levels were downregulated in these mice,
in parallel with the inhibition of SPT and ceramide content
[181].
In addition, PA may decrease levels of astroglial glucose
transporter and downregulate glucose uptake and lactate
release by astroglia. As astroglial uptake of glucose and sub-
sequent lactate production contribute to neuronal metabolic
activity and energy production, such findings suggest that,
beside an effect on ceramide content, saturated fatty acids
may result in detrimental changes in glucose metabolism
further contributing to AD pathogenesis [180].
In subsequent studies it was demonstrated that soluble
products released fromPA-activated human astroglia activate
neuronal N-SMase, increase ceramide levels, and provoke
cell death in primary neuronal cultures. Namely, PA-induced
activation of SPT and de novo synthesis of ceramides in
astrocytes leads to production of proinflammatory cytokines
TNF-𝛼 and IL-1𝛽. After release in surrounding media, these
soluble mediators activate SMases in neurons and increase
ceramide levels, BACE1, and ultimately A𝛽 level [182].
4. Ceramides and Inflammation
Immune activation within the brain is classical feature of
AD. Chronic neuroinflammation includes continuous acti-
vation of microglia and sustained release of inflammatory
mediators, together with resulting oxidative and nitrosative
stress [183, 184]. Following microglial activation numerous
neurotoxic molecules including cytokines, chemokines, exci-
totoxic molecules, and reactive oxygen and nitrous species
are released with detrimental consequences on neuronal
survival. For example, A𝛽 induced the expression of inducible
NO synthase (iNOS) and proinflammatory cytokines TNF-
𝛼, IL-1𝛽, and IL-6 in mouse primary microglia [185]. As
mentioned previously, some of these inflammatory media-
tors likely elicit production of ceramide via hydrolysis of
sphingomyelin after SMase activation, whereas ceramide in
turn could stimulate generation of ROS and initiate apoptotic
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cascade [54, 162]. The proinflammatory cytokine TNF-𝛼 acts
as strong activator of N-SMase coupled to TNF receptor
Type 1 (TNFR1) expressed on the surface of neuronal cells
through the adaptor protein FAN [186]. In response to TNF-
𝛼, signalling through TNFR1 receptor induces phospholipase
A2 activity, generation of arachidonic acid, and subsequent
activation of N-SMase as arachidonic acid cascade produces
4-HNE and diverse ROS [162, 187]. Furthermore, activity
of N-SMase preceded an accumulation of ROS by NADPH
oxidase. It is known that NADPH oxidase-dependent irre-
versible damage to sphingosine kinase-1 inhibits neurite
outgrowth of dorsal root ganglion neurons. Thus, TNF-𝛼-
induced N-SMase activation not only produces neurotoxic
mediators such as ceramide and ROS, but also directly
antagonizes neuronal survival. These findings suggest that a
shift in ceramide metabolism in combination with oxidative
stress likely exacerbates neuronal degeneration in AD and
other CNS pathologies exhibiting inflammation [66]. Simi-
larly, experiments performed on purified myelin frommouse
brain showed that TNF-𝛼 upon release activates myelin-
associated SMase resulting in ceramide production that
might have deleterious effects onmyelin integrity [188]. TNF-
𝛼 also affects growth and viability of GT1-7 hypothalamic
neurons through the ceramide-generating pathway [189].
The relationship between A𝛽 and oxidative stress in white
matter involving cytokine and ceramide is also established.
A𝛽 enhances TNF-𝛼-induced expression of iNOS and nitrite
generation in oligodendrocytes. A𝛽 and TNF-𝛼, alone or
in combination, increase activity of N-SMase leading to
ceramide accumulation [190].
5. Sphingomyelin/Ceramide Pathway as a
Therapeutic Approach in AD
Due to plethora of intrinsic factors affecting AD, it is
generally assumed that novel pharmacological approaches in
AD should rely on the simultaneous targeting of several steps
in the early stages of the disease. Considering reports that
intracellular accumulation of ceramides and neurotoxicity of
A𝛽 can be prevented with inhibitors of ceramide production,
it was suggested that sphingolipid metabolism might be a
promising target for AD [27]. Pharmacological inhibition
of sphingolipid biosynthesis may reduce A𝛽 production.
Thus, neurons treated with conditionedmedia obtained from
astroglia exposed to fatty acids and L-cycloserine, the SPT
inhibitor, displayed attenuated increase in A𝛽 levels [180].
Furthermore, subcutaneous administration of L-cycloserine
to the aforementioned early-onset mouse model of AD
effectively reduced cortical levels of SPT, together with
reduced ceramide levels, and downregulation of cortical A𝛽
production [181].
Minocycline, a semisynthetic second-generation tetra-
cycline derivative that effectively crosses the blood-brain
barrier, also exerts beneficial effects against sphingo-
myelinase/ceramide-induced neurotoxicity via antioxidative
and antiapoptotic mechanisms [191]. In particular, it showed
neuroprotective effects in rat cortical cultures against toxicity
induced by bacterial SMase and C2-ceramide, by enhancing
Bcl-2 expression via activation of the NO/cGMP/PKG
pathway and direct induction of PKG-1, in association with
increased expression of thioredoxin-1 [65]. Minocycline was
also effective in attenuating A𝛽-induced neuronal cell death
and deficits in learning and memory in A𝛽-infused rats
[192].
Besides acting on A𝛽 pathology, ceramides might affect
hyperphosphorylation of tau by modulating PP2A activity,
the principal phospho-tau phosphatase. Ceramides activate
PP2A in vitro and in rat brain, and inhibitor 2 of PP2A
(I2PP2A) was identified as a ceramide-binding protein that
through its specific interactions with ceramide prevents
inhibition of PP2A activity in vitro [193–195]. The enhance-
ment of the PP2A activity is considered promising as a
next generation of the AD therapeutic target [196]. Lithium
was found effective against ceramide-induced apoptosis via
inhibition of PP2A activity. Ceramide-induced activation
of PP2A involved methylation of PP2A C subunit, which
was suppressed by lithium. Lithium also exhibited anti-
apoptotic effect by inhibiting Bcl-2 dephosphorylation and
caspase-2 activation [197]. It is also suggested that PARP-1
inhibitors andmodulators of sphingosine-1-phosphate recep-
tors may represent a promising avenue in future therapeutic
approaches [70].
6. Conclusions
Ceramides affect various aspects of neuronal physiology
determining cell differentiation, growth, survival, senescence,
and apoptosis. Postmortem analyses of AD brains reveal
alterations of brain lipid profile and disturbed ceramide
metabolism indicating that preservation of ceramide home-
ostasis is a prerequisite for normal brain functioning. More-
over, increased ceramide levels are found in patients with
mild and moderate symptoms, suggesting that alterations
in ceramide metabolism occur in the early stages of the
disease. These findings pointed out that ceramides exert
important roles in the AD onset and progression. Numerous
evidences demonstrated that ceramides are detrimentally
associated with several pathological aspects of AD, including
A𝛽 accumulation, tau hyperphosphorylation, ROS genera-
tion,mitochondrial dysfunction, deregulation of intracellular
signalling pathways, initiation of apoptosis, and neurodegen-
eration.
Of particular interest is the critical role of ceramides in
mediating the production of A𝛽 and their link to oxidative
stress. Ceramides increase A𝛽 levels by reinforcing APP
processing via BACE1 stabilization. As soluble and fibrillar
forms of A𝛽 can activate both neutral and acidic SMases
through increased ROS accumulation via NADPH oxidase
activation and GSH depletion, initial ceramide formation
in a vicious cycle leads to more ceramide accumulation. In
addition to ceramide increase, oxidative stress is also one of
the earliest events inAD. Enhanced generation of free radicals
strongly contributes to toxic effects of both ceramides and
A𝛽, ultimately affecting neuronal functioning and survival.
Membrane oxidative stress seems to be particularly relevant
for AD, as accumulation of HNE, the toxic end-product
of lipid peroxidation, is closely related to the severity of
neurodegenerative changes.
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In spite of major research efforts, there is still no effective
AD treatment. A comprehensive understanding and identifi-
cation of molecular and biochemical alterations in ceramide
metabolic pathways and insight into their influence on the
pathophysiological processes during progression of AD are
indispensable for successful development of novel therapeu-
tic interventions. Strategies aimed at reducing ceramide levels
have the potential to prevent A𝛽 burden and slow down
progression of the disease. Further studies in vivo are needed
to establish proof of concept, particularly in combination
with other targets, such as those directed at detoxification of
ROS and preservation of redox homeostasis.
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